A Dear Healthcare Professional letter to physicians about important information concerning administration of Relenza (zanamivir)
24.11.2009
GlaxoSmithKline (GSK), in collaboration with the Agency for Medicinal Products and Medical Devices, sent a Dear Healthcare Professional letter to physicians about important information concerning administration of the medicinal product Relenza (zanamivir).
The purpose of the letter is to alert all physicians to important information concerning the administration of the medicinal product that are provided in the approved Summary of Product Characteristics and Patient Information Leaflet, in connection with chapters 4.2 Dosage and administration and 6.3 Expiry date.
The Agency for Medicinal Products and Medical Devices monitors the safe use of this medicinal product. All information, recommendations and forms regarding strengthened monitoring during the A/H1N1 influenza pandemic may be found on the website of the Agency.
The full text of the letter may be found below:
"Important information about the medicinal product: RELENZA (zanamivir) inhalation powder - changes to and important information concerning administration of the medicinal product"
